Experts warn the GLP-1 gold rush could put insulin supply at risk

The Access to Medicine Foundation's latest index warns that drugmakers' focus on lucrative weight-loss drugs such as Mounjaro, Wegovy and Ozempic risks pulling attention away from insulin, and that Sanofi, Lilly or Novo leaving the insulin market would hit supply badly. It notes Novo plans to phase out some older diabetes products, while GLP-1s remain unregistered or unaffordable in many lower-income countries.

Source: The Guardian (10 Nov 2026). Image: The Guardian.